About: Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.
Creator	Corti, Davide Wang, David Ding, Siyuan Zhao, Haiyan Wang, S Bloyet, Louis-Marie Diamond, Michael Amarasinghe, Gaya Liu, Z Case, James Chen, R Fremont, Daved Kim, Arthur Sidhu, Sachdev Virgin, Herbert Whelan, Sean Zhao, H Kim, S Liu, Zhuoming Theel, Elitza Amarasinghe, M Case, J Chen, Rita Corti, S Droit, Lindsay Henderson, Jeffrey Ilagan, G Kim, A Miersch, Shane Rothlauf, Paul Rothlauf, P Sidhu, M Tahan, Q Tahan, Stephen Tartell, M Tartell, Michael Ustav, Mart Ustav, S Whelan, D Xenia, Ma Zeng, Qiru Zeng, L.-M
Source	Elsevier; Medline; PMC
abstract	Abstract Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and possibly transmission. An anticipated correlate of such countermeasures is the level of neutralizing antibodies against the SARS-CoV-2 spike protein, which engages with host ACE2 receptor for entry. Using an infectious molecular clone of vesicular stomatitis virus (VSV) expressing eGFP as a marker of infection, we replaced the glycoprotein gene (G) with the spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2) and developed a high-throughput imaging-based neutralization assay at biosafety level 2. We also developed a focus-reduction neutralization test with a clinical isolate of SARS-CoV-2 at biosafety level 3. Comparing the neutralizing activities of various antibodies and ACE2-Fc soluble decoy protein in both assays revealed a high degree of concordance. These assays will help define correlates of protection for antibody-based countermeasures and vaccines against SARS-CoV-2. Additionally, replication-competent VSV-eGFP-SARS-CoV-2 provides a tool for testing inhibitors of SARS-CoV-2 mediated entry under reduced biosafety containment.
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.1016/j.chom.2020.06.021
bibo:pmid	32735849
has license	els-covid
sha1sum (hex)	8864fbda7c87d0cd60ecca154ff52fa8235bd52d
schema:url	https://doi.org/10.1016/j.chom.2020.06.021
resource representing a document's title	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.
has PubMed Central identifier	PMC7332453
has PubMed identifier	32735849
schema:publication	Cell Host Microbe
resource representing a document's body	covid:8864fbda7c87d0cd60ecca154ff52fa8235bd52d#body_text
is schema:about of	named entity 'protein' named entity 'soluble' named entity 'level' named entity 'Vesicular stomatitis virus' named entity 'encoding' named entity 'level' named entity 'define' named entity 'Journal' named entity 'SARS-CoV-2' named entity 'neutralization' named entity 'Spike' named entity 'SARS-CoV-2' named entity 'high' named entity 'containment' named entity 'engages' named entity 'soluble' named entity 'spike' named entity 'ACE2' named entity 'correlates' named entity 'level' named entity 'decoy' named entity 'SARS-CoV-2' named entity 'reduced' named entity 'truncation' named entity 'isolate' named entity 'soluble' named entity 'VSV' named entity 'vesicular stomatitis virus' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'antibodies' named entity 'biosafety level 3' named entity 'antibody' named entity 'doi' named entity 'Neutralizing antibody' named entity 'neutralization test' named entity 'Vesicular stomatitis virus' named entity 'SARS-CoV-2' named entity 'ACE2' named entity 'VSV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software